Heterocyclic Compounds

Matches 801 - 850 out of 36,875	< 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 >

Document	Document Title
WO/2023/142492A1	ORGANIC COMPOUND, ELECTRONIC COMPONENT, AND ELECTRONIC DEVICE The present application relates to the field of organic light-emitting materials, and in particular to an organic compound, an electronic component, and an electronic device. The structure of the organic compound is as represented by for...
WO/2023/142985A1	PREPARATION METHOD FOR TGF-β-INHIBITING ANTI-TUMOR DRUG The present invention belongs to the technical field of drug synthesis. Disclosed is a preparation method for a TGF-β-inhibiting anti-tumor drug. Compared with preparation methods in the existing technology, the number of reaction steps...
WO/2023/141432A2	APOL1 INHIBITORS AND METHODS OF USE Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. A...
WO/2023/138621A1	ATR INHIBITORS AND USES THEREOF The present disclosure relates to novel compounds useful as inhibitors of ATR kinase, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical c...
WO/2023/138583A1	HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Provided in the present invention are a heterocyclic compound, a pharmaceutical composition and the use thereof. Specifically disclosed are a heterocyclic compound as represented by formula (I-0), a pharmaceutically acceptable salt or st...
WO/2023/139085A1	NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
WO/2023/138676A1	TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF Disclosed in the present invention are a tricyclic fused heterocyclic compound having PDE3/4 dual inhibitory effect as represented by formula (I), and a stereoisomer, a solvate, or a pharmaceutically acceptable salt thereof, and the use ...
WO/2023/138336A1	METHOD FOR PREPARING FINERENONE AND INTERMEDIATE THEREOF Disclosed is a method for preparing a finerenone intermediate compound of formula (I) from a diastereomeric tartrate by means of racemic resolution. A compound of formula I having an ee value higher than 99.5% can be obtained. The prepar...
WO/2023/139402A1	INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed. Formula (C)
WO/2023/138541A1	PICOLINAMIDE PARP INHIBITOR, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Disclosed are a picolinamide PARP inhibitor, and a preparation method therefor and the medical use thereof. Specifically, the present invention relates to a new compound as represented by general formula (1) and/or a pharmaceutically acc...
WO/2023/138691A1	FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING Among others, the present invention provides fused heterocyclic compounds of Formula (I) or tautomers, stereoisomer, or pharmaceutically acceptable salts thereof. These compounds and compositions containing them are useful in the treatme...
WO/2023/141225A1	FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazo...
WO/2023/138512A1	SALT CRYSTAL FORM AND FREE BASE CRYSTAL FORM OF KINASE INHIBITOR A salt crystal form and a free base crystal form of a kinase inhibitor. Specifically, disclosed are a salt crystal form formed by a compound as shown in formula I and different acids, and a free base crystal form thereof.
WO/2023/139199A1	COMPOUNDS AND THEIR USE IN TREATING CANCER Compounds of Formula (I) or a pharmaceutically acceptable salt thereof are PROTAC compounds useful in the treatment of prostate cancer.
WO/2023/139479A1	SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS The present invention is directed to compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof that is useful as MALT-1 inhibitors for the treatment of a disease or disorder dependent on MALT-1...
WO/2023/138599A1	AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF An aromatic fused ring compound which acts as a sodium channel blocker, and a use thereof. The aromatic fused ring compound has inhibitory activity on sodium ion channel Nav1.8, and may be used as a drug for a wide range of pain treatment.
WO/2023/138254A1	HETEROCYCLIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT MATERIAL AND ELEMENT The present invention relates to a heterocyclic compound, an organic electroluminescent material, and an organic electroluminescent element. The structure of the heterocyclic compound is as shown in formula (I). The heterocyclic compound...
WO/2023/138589A1	FIVE-MEMBERED HETEROCYCLIC PYRIMIDINE DERIVATIVE AND USE THEREOF AS INHIBITOR OF PAN-KRAS MUTATION Provided are a five-membered heterocyclic pyrimidine derivative having a structural formula as shown in general formula (A) and a pharmaceutically acceptable salt thereof. The derivative has an inhibitory effect on a KRAS mutant, and in ...
WO/2023/138550A1	CYCLOPROPANAMIDE-CONTAINING COMPOUND AND USE THEREOF The present application relates to the field of pharmaceutical chemistry, and particularly relates to a cyclopropanamide-containing compound as represented by formula (I) and the use thereof. The cyclopropanamide-containing compound has ...
WO/2023/138695A1	CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a cathepsin K inhibitor having a structure as shown in formula (0) and/or formula (II), wherein cyanopyrimidine or a ketone serving as an electrophilic group is a key group to exert a good inhibition effe...
WO/2023/138317A1	COMPOUND HAVING RIPK1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a compound having RIPK1 inhibitory activity, a preparation method therefor and the use thereof. The structure of the compound is as shown in general formula I, and the definition of each substituent is as described in the d...
WO/2023/138526A1	CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND Provided is a crystal form of an allyl-containing methylpyridopyrimidine compound, and in particular crystal forms of a compound as shown in formula (I) and of a salt of the compound.
WO/2023/138612A1	HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and...
WO/2023/141290A1	PARP1 INHIBITORS AND USES THEREOF Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
WO/2023/134711A1	CYCLOPIPERIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a cyclopiperidine compound, a preparation method therefor, and a use thereof. The cyclopiperidine compound of the present invention is represented by formula I'. The cyclopiperidine compound of the present invention has a b...
WO/2023/134713A1	FUSED AZAHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF The present invention belongs to the field of medicines, and relates to a fused azaheterocyclic compound, a pharmaceutical composition thereof and the use thereof in the preparation of a drug. Specifically, the present invention relates ...
WO/2023/137353A1	15-PGDH INHIBITORS Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
WO/2023/137356A1	15-PGDH INHIBITORS Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
WO/2023/135233A1	AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.
WO/2023/137223A1	PAN-KRAS INHIBITORS AND USES THEREOF The disclosure includes compounds of Formula (3) wherein each of Warhead, R1, R2, R3, L1, L2, L3, L4, L5, L6, R0, Q1, Q2, Q3, W1, W2, m, n, and i, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmu...
WO/2023/135260A1	NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS The present disclosure provides compounds of formula (la) that are inhibitors of SOS1, pharmaceutical compositions thereof, and methods of treating oncological diseases using the compounds and compositions disclosed herein.
WO/2023/137041A1	COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
WO/2023/134688A1	SALT OF ROCK INHIBITOR, CRYSTAL FORM OF SALT, COMPOSITION, AND PHARMACEUTICAL USE A salt of a ROCK inhibitor, a crystal form of the salt, a composition, and a pharmaceutical use. The salt and the crystal form of the salt are an acid addition salt of a compound I and any acid in the following and a crystal form thereof...
WO/2023/134647A1	PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Provided are a piperazino ring derivative represented by formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition containing said compound, as well as the use of the compoun...
WO/2023/135528A1	HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS The present invention relates to heteroalicyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes a method of mak...
WO/2023/134708A1	THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Provided are compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including ...
WO/2023/134250A1	COMPOSITE MATERIAL, LIGHT-EMITTING DIODE, AND PREPARATION METHOD The present application discloses a composite material, a light-emitting diode, and a preparation method. The composite material comprises a first electron transport material and an indole-ring-containing compound doped into the first el...
WO/2023/134266A1	2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR A 2-piperidyl or 2-pyrazolyl substituted pyrimidine compound, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a s...
WO/2023/133256A1	PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS Pyrazolo[1,5-a]pyridin-2,3-yl amide compounds, such as those represented by Formula I, functioning as Kv7.2/7.3 channel activators, are used to treat a number of diseases, disorders and conditions associated with a Kv7 potassium channel,...
WO/2023/132369A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these.　Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
WO/2023/131271A1	PYRROLE FUSED-RING PYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention belongs to the technical field of medicine, and specifically relates to a pyrrole fused-ring pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention further relates to a...
WO/2023/133217A1	2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/133225A1	COMPOUNDS AND METHODS FOR MODULATING SPLICING The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/131868A1	HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of GLUT9 for the treatment or prevention of hyperuricemia and gout.
WO/2023/131122A1	FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention is a compound as represented by formula (IA) or formula (IC) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The definition of each group in the formula is shown i...
WO/2023/131118A1	PROTEIN DEGRADERS DEVELOPED ON BASIS OF BCL-2 FAMILY PROTEIN LIGAND COMPOUNDS AND USE THEREOF The present disclosure relates to protein degraders developed on the basis of BCL-2 family protein ligand compounds, comprising compounds of formula (I) or salts, enantiomers, stereoisomers, solvates, prodrugs or polymorphs thereof, and ...
WO/2023/131277A1	NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF The present application belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and the uses thereof, and particularly relates to a compound represented by general formula (A) or a pharmaceutically accepta...
WO/2023/133229A2	COMPOUNDS AND METHODS FOR MODULATING SPLICING The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/133375A1	MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as autoimmune disease.
WO/2023/125716A1	CLASS OF QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula ...

Matches 801 - 850 out of 36,875	< 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 >